Spots Global Cancer Trial Database for kras gene mutation
Every month we try and update this database with for kras gene mutation cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Phase 2 Study of TVB-2640 in KRAS Non-Small Cell Lung Carcinomas | NCT03808558 | KRAS Gene Mutat... | TVB-2640 | 18 Years - | University of Texas Southwestern Medical Center | |
| Phase 1b/2 Study of Futibatinib in Combination With Binimetinib in Patients With Advanced KRAS Mutant Cancer | NCT04965818 | Advanced or Met... Non-Small Cell ... KRAS Gene Mutat... | Futibatinib and... | 18 Years - | Taiho Oncology, Inc. | |
| I-MVAC +/- Panitumumab as First-line Treatment of Advanced Urothelial Carcinoma Without H-Ras Nor K-Ras Mutations | NCT02818725 | Infiltrating Ur... KRAS Gene Mutat... | Chemotherapy Panitumumab | 18 Years - | UNICANCER | |
| Expanded Access of Onvansertib With FOLFIRI and Bevacizumab for the Second-Line Treatment of Participants With KRAS-Mutated Metastatic Colorectal Cancer | NCT04446793 | Metastatic Colo... KRAS Gene Mutat... | Onvansertib Bevacizumab FOLFIRI | 18 Years - | Cardiff Oncology | |
| OPTImal PALliative Anti-epidermal Growth Factor Receptor Treatment in Metastatic Colorectal Cancer - | NCT03750175 | Colorectal Canc... Circulating Tum... KRAS Gene Mutat... NRAS Gene Mutat... BRAF Gene Mutat... Epidermal Growt... | Plasma circulat... | 18 Years - | Aarhus University Hospital | |
| Phase 2 Study of TVB-2640 in KRAS Non-Small Cell Lung Carcinomas | NCT03808558 | KRAS Gene Mutat... | TVB-2640 | 18 Years - | University of Texas Southwestern Medical Center | |
| French National Observatory of the Patients With Non-small Cell Lung (NSCLC) and Molecular Testings | NCT01700582 | Carcinoma, Non-... ALK Gene Mutati... KRAS Gene Mutat... BRAF Gene Mutat... | 18 Years - | Intergroupe Francophone de Cancerologie Thoracique | ||
| Binimetinib in Addition to Standard Chemotherapy in KRAS Mutated NSCLC. | NCT02964689 | Advanced Non-sm... KRAS Gene Mutat... Lung Cancer | Binimetinib Pemetrexed Cisplatin | 18 Years - 75 Years | Swiss Group for Clinical Cancer Research | |
| Frequency of EGFR and KRAS Mutations and Clinical-prognostic Correlation in Brazilian Lung Cancer Patients | NCT03171636 | Lung Neoplasms KRAS Gene Mutat... EGFR Gene Mutat... | 18 Years - | Hospital Erasto Gaertner | ||
| Trial of Trametinib and Ponatinib in Patients With KRAS Mutant Advanced Non-Small Cell Lung Cancer | NCT03704688 | Non Small Cell ... KRAS Gene Mutat... | Trametinib 0.5 ... Trametinib 1 MG Trametinib 1.5 ... Trametinib 2 mg Ponatinib 15 MG Ponatinib 30 MG | 19 Years - | Memorial Sloan Kettering Cancer Center | |
| Phase 1b/2 Study of Futibatinib in Combination With Binimetinib in Patients With Advanced KRAS Mutant Cancer | NCT04965818 | Advanced or Met... Non-Small Cell ... KRAS Gene Mutat... | Futibatinib and... | 18 Years - | Taiho Oncology, Inc. | |
| Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Positive Non-small Cell Lung Cancer | NCT02642042 | KRAS Gene Mutat... Recurrent Lung ... Stage IV Lung N... | Docetaxel Laboratory Biom... Trametinib | - | National Cancer Institute (NCI) | |
| Pembrolizumab and Trametinib in Treating Patients With Stage IV Non-Small Cell Lung Cancer and KRAS Gene Mutations | NCT03299088 | KRAS Gene Mutat... Metastatic Non-... Recurrent Non-S... Stage IV Non-Sm... | Pembrolizumab Trametinib | 18 Years - | University of California, Davis | |
| OPTImal PALliative Anti-epidermal Growth Factor Receptor Treatment in Metastatic Colorectal Cancer - | NCT03750175 | Colorectal Canc... Circulating Tum... KRAS Gene Mutat... NRAS Gene Mutat... BRAF Gene Mutat... Epidermal Growt... | Plasma circulat... | 18 Years - | Aarhus University Hospital | |
| Expanded Access of Onvansertib With FOLFIRI and Bevacizumab for the Second-Line Treatment of Participants With KRAS-Mutated Metastatic Colorectal Cancer | NCT04446793 | Metastatic Colo... KRAS Gene Mutat... | Onvansertib Bevacizumab FOLFIRI | 18 Years - | Cardiff Oncology | |
| Frequency of EGFR and KRAS Mutations and Clinical-prognostic Correlation in Brazilian Lung Cancer Patients | NCT03171636 | Lung Neoplasms KRAS Gene Mutat... EGFR Gene Mutat... | 18 Years - | Hospital Erasto Gaertner | ||
| Panitumumab With or Without Trametinib in Treating Patients With Stage IV Colorectal Cancer | NCT03087071 | EGFR NP_005219.... KRAS Gene Mutat... MAP2K1 Gene Mut... Metastatic Colo... Refractory Colo... Stage IV Colore... Stage IVA Color... Stage IVB Color... | Laboratory Biom... Panitumumab Trametinib | 18 Years - | M.D. Anderson Cancer Center | |
| Regorafenib and Methotrexate in Treating Participants With Recurrent or Metastatic KRAS Mutated Non-Small Cell Lung Cancer | NCT03520842 | KRAS Gene Mutat... Metastatic Mali... Recurrent Non-S... Stage IV Non-Sm... | Methotrexate Pharmacokinetic... Regorafenib | 18 Years - | Stanford University | |
| I-MVAC +/- Panitumumab as First-line Treatment of Advanced Urothelial Carcinoma Without H-Ras Nor K-Ras Mutations | NCT02818725 | Infiltrating Ur... KRAS Gene Mutat... | Chemotherapy Panitumumab | 18 Years - | UNICANCER | |
| Panitumumab With or Without Trametinib in Treating Patients With Stage IV Colorectal Cancer | NCT03087071 | EGFR NP_005219.... KRAS Gene Mutat... MAP2K1 Gene Mut... Metastatic Colo... Refractory Colo... Stage IV Colore... Stage IVA Color... Stage IVB Color... | Laboratory Biom... Panitumumab Trametinib | 18 Years - | M.D. Anderson Cancer Center | |
| Binimetinib in Addition to Standard Chemotherapy in KRAS Mutated NSCLC. | NCT02964689 | Advanced Non-sm... KRAS Gene Mutat... Lung Cancer | Binimetinib Pemetrexed Cisplatin | 18 Years - 75 Years | Swiss Group for Clinical Cancer Research | |
| Detection of KRAS, NRAS et BRAF Mutations in Plasma Circulating DNA From Patients With Metastatic Colorectal Cancer | NCT02751177 | Colorectal Canc... | KRAS, NRAS et B... | 18 Years - | Institut de Cancérologie de Lorraine |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
